Technology
Technology: Naked Biome’s drug discovery platform uses next-generation sequencing to profile healthy and diseased skin to identify unique microbial signatures that naturally aid in the defense against acne. Our multidisciplinary team of leading physicians, scientists, and industry experts are developing innovative approaches to expand the platform’s reach to discover probiotic treatments for other skin diseases with a microbial component including eczema, psoriasis and rosacea.
We’ve been selected to be a part of the Illumina Accelerator, allowing us access to the most advanced sequencing technologies and expertise.
Why now? The Human Microbiome project, initiated in 2009, has created a great foundation of information and technology, which is the basis of our new discoveries and solutions. Naked Biome’s ability to expand our database and advance clinical discoveries in human health is driven by the rapidly decreasing sequencing costs and readily accessible skin samples.
Naked Biome is a microbiome-based therapeutics company, launching advanced therapy to treat and prevent skin disease. They build an advanced drug discovery genomics platform for the treatment and continual improvement of skin diseases and health. Our proprietary microbiome-based approach to skin therapy leverages the power of beneficial bacteria on
the skin to eliminate harmful bacteria and restore skin to a healthy state. We have successfully completed a phase IB in acne demonstrating both safety and early trends in efficacy.
Illumina Accelerator Unveils Third Cycle of Genomics Startups
by Staff Writer 12/11/2015 Leave a Comment
Illumina Accelerator Unveils Third Cycle of Genomics Startups
Illumina Accelerator, a business accelerator focused solely on creating an innovation ecosystem for the genomics industry—has selected four new investments from its third funding cycle.
During the six-month Accelerator funding cycle, each startup will gain access to business guidance and fully operational lab space in the San Francisco Bay Area, as well as seed investment, a subscription to Illumina’s NextBio translational genomics database, Illumina’s Genologics Clarity LIMS software, access to match funding through the $40 million Illumina Accelerator Boost Capital, and Illumina’s sequencing systems and reagents.
Here is a look at Illumina’s third cycle of genomic-focused startups are:
– MetaMixis, Inc., a synthetic biology company spun out of The University of British Columbia, is specializing in the rapid discovery of enzymes and pathways to produce bio-based materials and chemicals.
– NextGen Jane, Inc., a novel med-tech company based on technology developed at Harvard University, is offering women insights into their reproductive health through a genomics-driven approach to tracking biological changes predictive of disease.
– Skinomics, Inc., a skin microbiome company formed by faculty members from the University of California, Los Angeles, is harnessing genomics information from the cutaneous microbiome to create advances in skin care, with a current focus on acne.
– Vitagene, Inc., a health technology company, is leveraging genomic science to offer physicians a platform for data-driven care and delivers highly customized products and services for optimal health.
“Illumina Accelerator continues to propel talented entrepreneurs by providing unparalleled resources to help advance their genomics startups,” said Amanda Cashin, Ph.D., co-founder and Head of Illumina Accelerator. “The quality and diversity of our four newest investments is an indicator of the potential impact of genomics in a range of different fields. We’re thrilled to have such an inspiring group join us for round three.”